Dalbavancin作为难治性糖尿病相关性足部骨髓炎患者的补救性治疗

IF 2.9 4区医学 Q2 INFECTIOUS DISEASES Infectious diseases now Pub Date : 2023-11-14 DOI:10.1016/j.idnow.2023.104835

Anne Boucher , Maxime Pradier , Barthelemy Lafondesmurs , Pauline Thill , Pierre Patoz , Nicolas Blondiaux , Donatienne Joulie , Benjamin Hennart , Olivier Robineau , Eric Senneville

{"title":"Dalbavancin作为难治性糖尿病相关性足部骨髓炎患者的补救性治疗","authors":"Anne Boucher , Maxime Pradier , Barthelemy Lafondesmurs , Pauline Thill , Pierre Patoz , Nicolas Blondiaux , Donatienne Joulie , Benjamin Hennart , Olivier Robineau , Eric Senneville","doi":"10.1016/j.idnow.2023.104835","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.</p></div><div><h3>Patients and methods</h3><p>Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.</p></div><div><h3>Results</h3><p>Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission.</p></div><div><h3>Conclusions</h3><p>In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.</p></div>","PeriodicalId":13539,"journal":{"name":"Infectious diseases now","volume":"54 1","pages":"Article 104835"},"PeriodicalIF":2.9000,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666991923001975/pdfft?md5=56a4a528d9a789d9120d4199d0cf9d1e&pid=1-s2.0-S2666991923001975-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis\",\"authors\":\"Anne Boucher , Maxime Pradier , Barthelemy Lafondesmurs , Pauline Thill , Pierre Patoz , Nicolas Blondiaux , Donatienne Joulie , Benjamin Hennart , Olivier Robineau , Eric Senneville\",\"doi\":\"10.1016/j.idnow.2023.104835\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.</p></div><div><h3>Patients and methods</h3><p>Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.</p></div><div><h3>Results</h3><p>Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission.</p></div><div><h3>Conclusions</h3><p>In the study, dalbavancin was well-tolerated and showed microbiological and clinical efficacy.</p></div>\",\"PeriodicalId\":13539,\"journal\":{\"name\":\"Infectious diseases now\",\"volume\":\"54 1\",\"pages\":\"Article 104835\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2023-11-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666991923001975/pdfft?md5=56a4a528d9a789d9120d4199d0cf9d1e&pid=1-s2.0-S2666991923001975-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious diseases now\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666991923001975\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious diseases now","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666991923001975","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

我们的目的是描述dalbavancin治疗糖尿病相关性足部骨髓炎患者的有效性和安全性，并进行骨培养证实。在2019年1月至2021年12月期间，所有连续接受至少1500mg剂量达尔巴文星治疗糖尿病相关足部骨髓炎的患者被纳入回顾性研究。缓解被定义为在末次给药后6个月的随访中没有复发性感染或不需要在初始或连续部位进行手术。纳入13例患者。11例(85%)患者接受手术治疗。6例(46%)患者因既往治疗相关不良事件接受达巴伐辛一线治疗，7例(54%)患者接受达巴伐辛二线治疗。报告了一例不良事件。在6个月的随访中，11例患者可评估，9例(82%)缓解。在研究中，达尔巴万辛耐受性良好，并显示出微生物学和临床疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Dalbavancin as salvage therapy in difficult-to-treat patients for diabetes-related foot osteomyelitis

Objectives

We aimed to describe the efficacy and safety of dalbavancin in treatment of patients with diabetes-related foot osteomyelitis with bone culture confirmation.

Patients and methods

Between January 2019 and December 2021, all consecutive patients receiving at least one 1500 mg dose of dalbavancin for diabetes-related foot osteomyelitis were included in a retrospective study. Remission was defined as absence of relapsing infection or need for surgery at the initial or a contiguous site during 6-month follow-up from the last dose of dalbavancin.

Results

Thirteen patients were included. Eleven (85%) patients were surgically treated. Six (46%) patients received dalbavancin as first-line treatment and 7 (54%) as second-line treatment due to adverse events related to previous treatments. One adverse event was reported. At 6-month follow-up, 11 patients were evaluable and 9 (82%) were in remission.